Core Insights - Daxor Corporation will showcase its advanced blood volume analysis technology at the 45th International Society for Heart and Lung Transplantation Annual Meeting, which will take place from April 27-30, 2025, in Boston, MA, attracting around 3,500 specialists in heart and lung disease treatment [1][2] Company Overview - Daxor Corporation is recognized as the global leader in blood volume measurement technology, having developed the BVA-100® (Blood Volume Analyzer), the only FDA-cleared diagnostic blood test for quantifying blood volume status and composition [3] - Over 65,000 tests have been conducted at leading hospitals in the U.S., significantly improving hospital performance metrics and reducing mortality and readmissions in heart failure and critical care [3] - The company is engaged in ongoing trials for heart failure treatment with support from the NIH and is also developing analyzers for combat casualty care in collaboration with the U.S. Department of Defense [3] Technology and Impact - Daxor's diagnostic technology provides 98% accurate data, facilitating personalized treatment for end-stage heart and lung patients, which enhances patient outcomes while lowering care duration and costs [2]
Daxor Corporation to Exhibit at the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions